Diamide macrocycles that are FXIa inhibitors
US10081623B2 · kind B2 · utility
0Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2015 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Sep 3, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.